Namur Thrombosis and Hemostasis Center

Activities

Activities per year 2011 2013 2014 2016 2017 2018 2019 2022 2023 2023

• 48 Participation in conference
• 46 Invited talk
• 31 Publication peer-review
• 29 Oral presentation
• 40 More
  • 18 Participation in workshop, seminar, course
  • 4 Consultancy
  • 4 External Thesis
  • 4 Membership of committee
  • 3 Research/Teaching in a external institution
  • 2 Membership of council
  • 1 Participation to a Symposium, a study Day
  • 1 Editorial activity
  • 1 Jury
  • 1 Membership of board
  • 1 Membership of network

Activities per year

Search results

• Impact of progestagen alone or associated with estrogen on the coagulation: A state of the art in 2023

  Douxfils, J. (Speaker)

  1 Dec 2023

  Activity: Talk or presentation types › Invited talk

• Hemostasis parameters with estetrol/drospirenone - why APC resistance matters

  Douxfils, J. (Speaker)

  30 Nov 2023

  Activity: Talk or presentation types › Invited talk

• Combined Hormonal Contraceptives - Induced Coagulopathies Evaluation of the Prothrombotic State Using a Global Coagulation Assay

  Douxfils, J. (Speaker) & Morimont, L. (Speaker)

  4 Oct 2023

  Activity: Talk or presentation types › Invited talk

• Donesta Partner Meeting : Acquired APC resistance as a marker for VTE, how does the estrogens differ?

  Douxfils, J. (Keynote speaker)

  4 Sept 2023 → 8 Sept 2023

  Activity: Talk or presentation types › Invited talk

• Safety profile of E4: Recent advance and evidence

  Douxfils, J. (Keynote speaker)

  18 Sept 2023

  Activity: Talk or presentation types › Invited talk

• Aquired APC-resistance as a marker for VTE, how reliable?

  Douxfils, J. (Invited speaker)

  27 Aug 2023

  Activity: Talk or presentation types › Invited talk

• Évaluation du risque vasculaire des contraceptifs

  Douxfils, J. (Invited speaker)

  21 Jun 2023 → 23 Jun 2023

  Activity: Talk or presentation types › Invited talk

• Risque induit par les oestrogènes de synthèse en clinique

  Douxfils, J. (Invited speaker)

  8 Jun 2023

  Activity: Talk or presentation types › Invited talk

• APC resistance as a marker of the risk of VTE in users of oral contraceptives. Practical usefulness for industry and for clinicians

  Douxfils, J. (Invited speaker)

  26 May 2023

  Activity: Talk or presentation types › Invited talk

• Estétrol: une nouvelle ère dans la contraception

  Douxfils, J. (Invited speaker)

  11 Feb 2023

  Activity: Talk or presentation types › Invited talk

• Thromboembolie veineuse et contraception orale: Quelle stratégie pour minimiser le risque?

  Douxfils, J. (Invited speaker) & Morimont, L. (Speaker)

  12 Jan 2023

  Activity: Talk or presentation types › Invited talk

• Drug monitoring of direct oral anticoagulants: Key considerations and prespectives

  Douxfils, J. (Speaker)

  3 Nov 2022

  Activity: Talk or presentation types › Invited talk

• Hormonal contraception and the risk of venous thrombosis – facts and myths

  Douxfils, J. (Speaker)

  18 Nov 2022

  Activity: Talk or presentation types › Invited talk

• Global coagulation assays in the future of laboratory diagnostics of hemostasis and thrombosis - Interplay between platelets and coagulation

  Douxfils, J. (Keynote speaker)

  24 Nov 2022

  Activity: Talk or presentation types › Invited talk

• Acquired APC resistance as a marker for VTE, how reliable?

  Douxfils, J. (Speaker)

  7 Oct 2022

  Activity: Talk or presentation types › Invited talk

• Beeak-out Medical: Hemostasis and update on the Post Authorization Safety Study

  Douxfils, J. (Speaker) & Chatel, G. (Speaker)

  13 Sept 2022

  Activity: Talk or presentation types › Invited talk

• Method validation for haemostasis assays: Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women. An unmet clinical and regulatory need

  Douxfils, J. (Speaker)

  15 Sept 2022

  Activity: Talk or presentation types › Invited talk

• Impact of E4 on hemostasis — Key messages to understand its unique safety profile

  Douxfils, J. (Speaker)

  13 Sept 2022

  Activity: Talk or presentation types › Invited talk

• Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity

  Douxfils, J. (Speaker)

  4 Jul 2022

  Activity: Talk or presentation types › Invited talk

• L’associazione Estetrolo/Drospirenone: approfondimento sui parametri ematocoagulativi | Why APC resistance matters?

  Douxfils, J. (Speaker)

  14 Jun 2022

  Activity: Talk or presentation types › Invited talk

• Impact des traitements hormonaux sur l’hémostase et exploration biologique : développement et perspectives actuelles 

  Douxfils, J. (Speaker)

  7 Jun 2022

  Activity: Talk or presentation types › Invited talk

• Monitoring des anticoagulants: Artéfacts ou avantages - Anticoagulants directs oraux

  Douxfils, J. (Speaker)

  20 Jun 2022

  Activity: Talk or presentation types › Invited talk

• Safety profile of E4: recent clinical evidence

  Douxfils, J. (Speaker)

  12 May 2022

  Activity: Talk or presentation types › Invited talk

• Impact des traitements hormonaux sur l’hémostase et exploration biologique : développement et perspectives actuelles 

  Douxfils, J. (Speaker)

  17 May 2022

  Activity: Talk or presentation types › Invited talk

• In vitro and in vivo models of cardiac ischemia : Past and Future

  Laloy, J. (Speaker)

  21 Mar 2022

  Activity: Talk or presentation types › Invited talk

• 10 ans de monitoring des anticoagulants oraux. Où en sommes-nous et où allons-nous?

  Douxfils, J. (Speaker)

  15 Mar 2022

  Activity: Talk or presentation types › Invited talk

• Estétrol/drospirénone, le point de vue de l’hém(ost)ato(sio)logue

  Douxfils, J. (Speaker)

  26 Jan 2022

  Activity: Talk or presentation types › Invited talk

• Measurement of Direct Oral Anticoagulants and Contact Pathway Inhibitors

  Douxfils, J. (Invited speaker)

  18 Jul 2021

  Activity: Talk or presentation types › Invited talk

• Thrombotic risk associated with COVID- 19 pathogenesis and unusual thrombosis associated with thrombocytopenia in the context of COVID-19 vaccination

  Douxfils, J. (Invited speaker)

  24 Jun 2021

  Activity: Talk or presentation types › Invited talk

• Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients After Two Doses of BNT162b2

  Favresse, J. (Invited speaker) & Douxfils, J. (Invited speaker)

  7 Jun 2021

  Activity: Talk or presentation types › Invited talk

• Estetrol (E4): Impact on hemostasis

  Douxfils, J. (Invited speaker)

  24 May 2021

  Activity: Talk or presentation types › Invited talk

• Neutralizing antibodies in COVID-19: Current knowledge and perspectives

  Douxfils, J. (Invited speaker)

  16 Mar 2021

  Activity: Talk or presentation types › Invited talk

• Utilisation des tests chromogéniques anti-FXa dans le cadre du suivi de l’HNF et des HBPM: principes de base et recommandations

  Douxfils, J. (Invited speaker)

  9 Feb 2021

  Activity: Talk or presentation types › Invited talk

• Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need

  Douxfils, J. (Invited speaker) & Morimont, L. (Invited speaker)

  4 Feb 2021

  Activity: Talk or presentation types › Invited talk

• Restoring faith in COC - An important hemostasis update

  Douxfils, J. (Speaker)

  2 Dec 2020

  Activity: Talk or presentation types › Invited talk

• Monitoring of anticoagulant drugs

  Douxfils, J. (Speaker)

  16 Sept 2020

  Activity: Talk or presentation types › Invited talk

• How to Measure Lupus Anticoagulants During DOAC Treatment?

  Douxfils, J. (Speaker)

  12 Jul 2020

  Activity: Talk or presentation types › Invited talk

• The Namur Thrombosis and Hemostasis Center A gathering of experts from laboratory, clinical and regulatory field

  Douxfils, J. (Invited speaker)

  19 Mar 2019

  Activity: Talk or presentation types › Invited talk

• Réunion de Consensus INAMI/RIZIV

  Douxfils, J. (Speaker)

  30 Nov 2017

  Activity: Talk or presentation types › Invited talk

• BHS Course - Antithrombotic therapy

  Douxfils, J. (Speaker)

  10 Dec 2016

  Activity: Talk or presentation types › Invited talk

• La génération de thrombine: une technique innovante pour le suivi des anticoagulants directs oraux - Standardisation et développements requis pour une implémentation en clinique

  Douxfils, J. (Invited speaker)

  21 May 2015

  Activity: Talk or presentation types › Invited talk

• Le « calibrated automated thrombogram » : une technique innovante pour mesurer la génération de thrombine.Principe, standardisation et intérêt clinique.

  Douxfils, J. (Invited speaker)

  16 Oct 2014

  Activity: Talk or presentation types › Invited talk

• Quelle place pour l'exploration biologique de l'hémostase à l'heure des NACOs?

  Douxfils, J. (Invited speaker)

  13 Jan 2014

  Activity: Talk or presentation types › Invited talk

• Le rôle du laboratoire dans la gestion des anticoagulants oraux directs

  Douxfils, J. (Invited speaker)

  30 Jan 2014

  Activity: Talk or presentation types › Invited talk

• Application clinique de la génération de thrombine pour le suivi de l’anticoagulation orale

  Douxfils, J. (Invited speaker)

  8 Oct 2013

  Activity: Talk or presentation types › Invited talk

• Le Monitoring des Nouveaux Anticoagulants Oraux

  Douxfils, J. (Invited speaker)

  27 Sept 2012

  Activity: Talk or presentation types › Invited talk